Genitourinary Cancer

Panel 03 - (INTERACTIVE) Hypofractionated Radiation Therapy for Localized Prostate Cancer: ASTRO, ASCO, and AUA Guideline Recommendations and Evidentiary Base

Key Questions 5-8: Technical issues for hypo-fractionated RT - normal tissue dose constraints, treatment volumes, and use of IGRT and IMRT

Sunday, October 21
5:39 PM - 5:57 PM
Location: Lila Cockrell Theatre

Mark Buyyounouski, MD, MS

Disclosure:
Employment
Stanford University: Professor: Employee

Compensation
Elsevier: Honoraria; Wolters Kluwer: Honoraria

Biography:
Mark Buyyounouski is a Professor of Radiation Oncology at Stanford University. Mark is the Director of Genitourinary Cancer and has a research focus on prostate cancer. He was a co-invcestigator in the Fox Chase Phase III trial comparing convetional and hypofractionated radiotherapy for intact prostate cancer. He is also a NRG Oncology primary investigator and lead GU003: A Randomized Phase III Trial Of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT).

Presentation(s):

Send Email for Mark Buyyounouski


Assets

Key Questions 5-8: Technical issues for hypo-fractionated RT - normal tissue dose constraints, treatment volumes, and use of IGRT and IMRT



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Key Questions 5-8: Technical issues for hypo-fractionated RT - normal tissue dose constraints, treatment volumes, and use of IGRT and IMRT